# Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer

> **NCT06479239** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Virginia** · enrollment: 23 (estimated)

## Conditions studied

- Pancreas Cancer
- Pancreatic Cancer

## Interventions

- **DRUG:** EGFR FPBMC

## Key facts

- **NCT ID:** NCT06479239
- **Lead sponsor:** University of Virginia
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-06
- **Primary completion:** 2027-12
- **Final completion:** 2031-06
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06479239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06479239, "Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06479239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*